Chief Scientific Officer
Dr. Seeger joined Optum in 2001. In addition to this role, Dr. Seeger is adjunct faculty at Harvard T.H. Chan School of Public Health. Dr. Seeger received a PharmD from the University of Arizona, an MPH from the University of Michigan and a DrPH from Harvard School of Public Health. Trained as a clinical pharmacist, Dr. Seeger spent three years on the faculty of the University of Illinois at Chicago, where he also completed a residency in pharmacy practice. He also spent five years on faculty at Harvard Medical School, Division of Pharmacoepidemiology. Dr. Seeger's research interests are predictors of drug therapy and the application of research methods that incorporate these predictors. He has worked extensively with propensity scores and related methods that seek to mitigate confounding by modeling drug therapy. He has applied these methods to research involving a wide range of therapeutic areas, including diabetes and rheumatologic, cardiovascular, neurologic and gastrointestinal disorders, as well as in vaccine safety and drug effects in pregnancy. Most of this work has involved the application of health insurance claims data as a foundation for studies of post-marketing drug safety. However, the availability of new data resources (particularly electronic health records) has expanded the range of questions that can be addressed through observational techniques and correspondingly expanded the scope of Dr. Seeger's work. He has authored or co-authored more than 100 articles in peer-reviewed medical literature and is a long-term member, past President, and Fellow of the International Society for Pharmacoepidemiology.